Details of the Drug Combinations

General Information of This Drug (ID: DMH5LME)

Drug Name
Levoleucovorin   DMH5LME
Synonyms FUSILEV (TN)
Indication
Disease Entry ICD 11 Status REF
Anemia 3A00-3A9Z Approved [1]
Colon adenocarcinoma N.A. Approved [2]
Colorectal carcinoma N.A. Approved [2]
Non-small-cell lung cancer 2C25.Y Approved [2]
Pervasive developmental disorder 6A00-6A0Z Approved [2]
Pneumocystis pneumonia CA40.20 Approved [2]
Rectal adenocarcinoma 2B92 Approved [2]
Rectum mucinous adenocarcinoma N.A. Approved [2]
Colon cancer 2B90.Z Investigative [2]
Colon mucinous adenocarcinoma N.A. Investigative [2]
Gastric cancer 2B72 Investigative [2]
Megaloblastic anemia N.A. Investigative [2]
Methotrexate toxicity N.A. Investigative [2]
⏷ Show the Full List of Indication(s)
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Pralatrexate + Levoleucovorin DCVPMTF Pralatrexate Non-Small Cell Lung Cancer [3]
------------------------------------------------------------------------------------

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Levoleucovorin FDA Label
3 ClinicalTrials.gov (NCT01820091) Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn